Atherosclerosis in Rheumatoid Arthritis: The Role of NETs and Management Authors: Yezhou Qian, Feige Nian, Hao Zhang, BinFeng Mo Published: 2026 ABSTRACT AbstractRheumatoid arthritis (RA), a chronic inflammatory autoimmune disease, is associated with an increased the risk of cardiovascular disease (CVD), with atherosclerosis as the primary pathological basis. Neutrophil extracellular traps (NETs) represent a plausible pathogenic contributor and biomarker candidate linking RA to accelerated atherosclerosis. This review summarizes the key regulatory factors for the formation of NETs in RA, including autoantibodies, proinflammatory cytokines, cellular crosstalk, post-translational modifications, impaired clearance and neutrophil heterogeneity. Notably, most available supporting evidence is derived from mechanistic studies, preclinical models and associative clinical observations, rather than definitive causal interventional trials. Accumulating evidence suggests that NETs may contribute to RA-associated atherosclerosis via three proposed pathways: endothelial dysfunction, inflammatory plaque progression and instability, and thrombosis. Additionally, this review outlines the multimodal management strategies, encompassing NETs-targeted interventions, RA inflammation control, traditional CVD risk management and biomarker-guided risk stratification. NETs hold promise as a potential therapeutic target to mitigate CVD morbidity and mortality in patients with RA, though further translational and clinical validation is needed.Keywords: rheumatoid arthritis, neutrophil extracellular traps, atherosclerosis, cardiovascular disease, management Introduction Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting approximately 18 million individuals globally.1 Characterized by joint pain, cartilage destruction, bone erosion and subsequent joint deformity, RA leads to substantial impairment of quality of life and increased disability.2 The pathophysiology of RA involves dysregulation of tissue-destructive molecules and proinflammatory cytokines, notably tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6).3 Beyond articular manifestations, RA is associated with a spectrum of systemic complications, including respiratory, neurological and cardiovascular disorders.4 Notably, cardiovascular disease (CVD) stands as the primary driver of increased long-term mortality in patients with RA.5 Importantly, conventional cardiovascular risk factors remain clinically relevant in patients with RA but do not fully explain the excess CVD burden in this population, which is additionally mediated by the persistent high-grade inflammatory milieu inherent to RA.6 In recent years, a growing body of evidence has implicated neutrophil extracellular traps (NETs) as key contributors to the pathogenesis of RA.7 NETs, extracellular structures released by neutrophils, consist of a DNA scaffold associated with citrullinated histone H3 (Cit H3) and cytotoxic enzymes, including neutrophil elastase (NE) and myeloperoxidase (MPO).8 Beyond their physiological role in pathogen clearance, excessive NETs accumulation in the circulation and synovial fluid of patients with RA is thought to perpetuate inflammation and exacerbate joint damage.9 CVD, predominantly driven by atherosclerosis, remains the leading cause of morbidity and mortality globally.10 Atherosclerosis is a progressive, lipid-driven inflammatory disorder of the arterial wall that evolves across a well-defined pathological continuum: endothelial dysfunction represents the earliest subclinical abnormality; sustained lipid deposition and inflammatory cell infiltration promote subclinical atherosclerosis with increasing plaque burden; advanced fibrous plaques may undergo structural deterioration leading to plaque instability; and eventual plaque rupture or superficial erosion triggers atherothrombosis, which causes acute vessel occlusion and precipitates clinical CVD events.11 This entire pathological process is underpinned by endothelial injury, accumulation of oxidized low-density lipoprotein (ox-LDL) and infiltration of inflammatory cells and cytokines.12 Accumulating evidence suggests that RA accelerates the development of atherosclerosis.13 Furthermore, RA and atherosclerosis share key pathophysiological features, including chronic inflammation and immune activation.14 NETs not only induce acute inflammation but also contribute to multiple stages of atherosclerotic pathogenesis.15 Additionally, NETs have been proposed as biomarkers and potential therapeutic targets for the diagnosis and prognosis of atherosclerosis-related diseases.16 Consistently, increased NETs release by neutrophils correlates with the RA disease activity.17 Given the high prevalence of atherosclerosis in RA, the established pathogenic role of NETs in atherosclerosis and the elevated NETs levels observed in RA, NETs are hypothesized to play a crucial role in the initiation and progression of atherosclerosis in patients with RA. Notably, direct human evidence linking NETs specifically to clinical cardiovascular outcomes in RA remains limited: most available data derive from cross-sectional associative studies using subclinical vascular surrogates rather than prospective studies with hard clinical endpoints, and many mechanistic insights are extrapolated from preclinical models or other inflammatory conditions. Although the associations among RA, NETs, vascular inflammation and atherosclerosis have been summarized in prior reviews, no prior work has systematically integrated the full translational pathway from RA-specific NETs dysregulation to atherosclerotic vascular outcomes, stratified all supporting evidence by study design and RA-specificity, and directly compared the cardiovascular profiles of conventional disease-modifying therapies versus investigational NETs-targeted interventions. This work provides three distinct incremental contributions. First, it presents a structured evaluation of RA-specific human clinical evidence and explicitly distinguishes findings derived from RA patients, preclinical arthritis-atherosclerosis models, and extrapolations from other inflammatory diseases. Second, it organizes the supporting data into a translational evidence hierarchy to clarify the maturity of each pathogenic pathway and therapeutic strategy. Third, it offers a critical comparison between conventional disease-modifying antirheumatic therapies and direct NET-targeted interventions with respect to cardiovascular protection, highlighting unmet needs in clinical translation. This review aims to summarize the mechanisms underlying NETs formation in RA, the contributions of NETs to RA-associated atherosclerosis, and the corresponding management strategies. Literature Search and Evidence Selection This work was conducted as a narrative review. A comprehensive literature search was performed across three electronic databases: PubMed, Embase, and Web of Science, covering all relevant publications from database inception to December 2025. The core search strategy combined terms including “rheumatoid arthritis”, “neutrophil extracellular traps”, “NETs”, “atherosclerosis”, “cardiovascular disease”, “endothelial dysfunction”, “plaque instability”, “thrombosis”, “PAD4 inhibitor”, “deoxyribonuclease” and “disease-modifying antirheumatic drugs”. Only peer-reviewed original research articles, systematic reviews, and meta-analyses and high-quality narrative reviews published in English were considered eligible. Conference abstracts, case reports, letters, commentaries, and non-English publications were excluded from the analysis. Two authors independently screened titles and abstracts to identify eligible studies, and any discrepancies were resolved through consensus discussion. For evidence prioritization, human clinical studies enrolling patients with RA were assigned the highest level of evidence, followed by preclinical studies using RA and atherosclerosis animal models. Evidence extrapolated from other inflammatory or autoimmune diseases was included only when direct RA-specific data were unavailable, and is explicitly distinguished throughout the manuscript. For clinical management recommendations, priority was given to international clinical practice guidelines and large-scale prospective cohort studies. The quality of included clinical studies was evaluated based on study design, sample size, and adjustment for confounding factors, while preclinical studies were assessed for methodological rigor and experimental reproducibility. The Formation of NETs in RA Neutrophils, as the most abundant innate immune cells in peripheral blood, play an important role in the pathophysiology of RA and are involved in the regulation of RA immunopathology.18 Neutrophils are a crucial cellular component infiltrating the synovial tissue of patients with RA, mediating RA by promoting inflammatory processes and cartilage degradation.19 Existing studies indicate that neutrophils in RA demonstrate an enhanced capacity to form NETs, and the levels of NETs are associated with the disease state of RA.20,21 NETosis is a heterogeneous process rather than a single uniform pathway. It could occur via lytic NETs release (a lytic cell death form with plasma membrane rupture) or vital NETs release (from viable neutrophils without immediate lysis).22 At the molecular level, NETs formation includes both peptidylarginine deiminase 4 (PAD4)-dependent (histone citrullination-mediated chromatin decondensation) and PAD4-independent pathways, as well as ROS-dependent and ROS-independent signaling cascades.23 Methodologically, circulating NETs biomarkers cannot fully distinguish NETs-derived DNA from cell-free DNA released by necrosis or other cell death forms, posing interpretive challenges.24 Functionally, NETs exert context-dependent dual roles: physiological pathogen clearance in host defense, versus pathogenic pro-inflammatory and tissue-damaging effects in chronic inflammatory conditions such as RA.22 The formation of NETs in patients with RA is a complex process regulated by multiple factors, including autoimmune responses, proinflammatory cytokines, cellular interactions and post-translational modifications. Autoantibody-Mediated NETs Formation Autoantibodies, a hallmark of RA, are key triggers for NETs formation. Anti-citrullinated protein antibodies (ACPAs), one of the most well-characterized autoantibodies in RA, directly activate neutrophils to release NETs.25 ACPAs bind to citrullinated proteins on the surface of neutrophils, initiating downstream signaling pathways that promote NETosis.26 For instance, ACPAs-stimulated neutrophils exhibit increased spontaneous NETs propensity in vitro, and this effect is potentiated by RA synovial fluid.26,27 Additionally, rheumatoid factor, another common autoantibody in RA, contributes to NETs formation by forming immune complexes that activate neutrophils via Fc receptor gamma chain (FcRγ) signaling.28 These immune complexes not only induce NETs release but also enhance the proinflammatory potential of NETs by promoting the externalization of citrullinated autoantigens.26 Recent studies have also identified anti-NETs antibodies (ANETA) in RA sera, which may further amplify NETs formation through a positive feedback loop, although their exact role remains to be fully elucidated.29 Cytokine-Driven NETs Formation The proinflammatory cytokine milieu in RA joints is a critical regulator of NETosis. Interleukin-33 (IL-33), whose levels are significantly elevated in RA synovial fluid and correlate with NETs markers, such as Cit H3-DNA and MPO-DNA, directly activates neutrophils to form NETs.30 IL-33-induced NETs formation is concentration- and time-dependent, requiring the production of reactive oxygen species (ROS), PAD4-mediated citrullination and NE activity.30 Mechanistically, IL-33 binds to its receptor ST2 on neutrophils, recruiting adaptor proteins MyD88 and TRAF6 to activate MAPK/ERK, p38 MAPK and NF-κB signaling pathways.30 Other cytokines, such as IL-8, IL-17 and TNF-α, also contribute to the formation of NETs in RA.31,32 IL-8 and IL-17 recruit neutrophils to inflammatory sites and prime them for NETosis, while TNF-α enhances neutrophil activation and NETs release by upregulating surface receptors and intracellular signaling cascades.19,33 Cellular Interactions Promoting NETs Formation Cellular crosstalk within the RA synovial microenvironment amplifies NETs formation. Fibroblast-like synoviocytes (FLS), a key cell type in RA joints, interact with NETs to create a proinflammatory feedback loop.34 NETs activate FLS via Toll-like receptor 9 (TLR9) signaling, inducing FLS to secrete IL-33 and chemokine CXCL8.30 (Revision 8) IL-33 further stimulates neutrophils to form NETs, while chemokine CXCL8 recruits additional neutrophils to the synovium, perpetuating inflammation.30 Moreover, FLS internalize citrullinated peptides from NETs and present them to T cells, enhancing adaptive immune responses and further promoting NETs formation.35 Macrophages also contribute to NETosis by secreting proinflammatory cytokines, such as IL-1β and TNF-α, then activating neutrophils through intercellular contact.36 Additionally, platelets in RA may interact with neutrophils to induce NETs formation, although the exact mechanism requires further investigation.37 Post-Translational Modifications and NETs Formation Post-translational modifications (PTMs) of proteins play a crucial role in regulating NETs formation and function in RA. Citrullination, catalyzed by PAD enzymes (primarily PAD4), is a well-characterized PTM that promotes chromatin decondensation and NETs release.38 Neutrophils from patients with RA exhibit increased PAD4 expression and activity, leading to enhanced citrullination of histones and other proteins in NETs.39 Carbamylation, another PTM linked to RA, also enhances NETs formation and osteoclastogenesis.40 Carbamylated NETs exhibit increased proinflammatory potential and induce rapid osteoclast formation through TLR4 signaling, contributing to bone erosion in RA.9 Furthermore, the mitochondrial DNA (mtDNA) levels in patients with RA were significantly higher than those in healthy individuals.41 Extrapolated evidence from studies in other autoimmune diseases shows that oxidation of mtDNA in NETs enhances their immunostimulatory capacity, promoting type I interferon (IFN) production and exacerbating inflammation.42,43 Impaired NETs Clearance and Accumulation In addition to enhanced formation, impaired clearance of NETs contributes to their accumulation in RA joints. Deoxyribonuclease I (DNase I), a key enzyme responsible for NETs degradation, exhibits reduced activity in patients with RA.44 Genetic variations in deoxyribonuclease 1-like 3 (DNase1L3), another enzyme involved in NETs clearance, are also associated with RA susceptibility and impaired NETs degradation.45 The accumulation of uncleared NETs prolongs the exposure of autoantigens to the immune system, promoting autoantibody production and sustaining inflammation.35 Moreover, uncleared NETs may directly damage tissues by releasing cytotoxic components such as histones and NE, while simultaneously activating inflammatory signaling pathways.40 Neutrophil Heterogeneity and NETs Formation Neutrophil heterogeneity contributes to the dysregulated NETs formation in RA. Low-density granulocytes (LDGs) represent a granulocyte subset with altered buoyant density that is enriched in the peripheral blood of RA patients.46 Phenotypic and functional features specifically demonstrated in RA include higher spontaneous NET formation capacity, elevated PAD4 expression and ROS production, an immature granulocyte phenotype with upregulated proinflammatory gene signatures, and reduced apoptosis.47,48 These properties collectively promote enhanced NETs release and sustain inflammatory cascades in RA. LDGs do not constitute a single standardized cell population. Their phenotypic and functional characteristics could be substantially influenced by isolation protocols, particularly density gradient centrifugation methods, which may co-isolate immature granulocyte precursors and activated neutrophils.48 Of note, some reported pathogenic functions of LDGs—such as direct endothelial cytotoxicity and type I interferon induction—have been primarily demonstrated in systemic lupus erythematosus, multiple sclerosis and neuromyelitis optica spectrum disorder,49–51 whether equivalent pathogenic profiles exist universally in RA LDGs requires further targeted investigation. The presence of LDGs and their enhanced ability to form NETs may explain the increased NETs levels observed in RA synovial fluid and serum.30,50 The pathogenesis of the formation of NETs in RA is shown in Figure 1. The pathogenesis of the formation of NETs in RA. Abbreviations: ACPA, anti-citrullinated protein antibodies; FcRγ, Fc receptor gamma chain; IL, interleukin; MAPK, mitogen activated protein kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; ROS, reactive oxygen species; PAD-4, peptidylarginine deiminase 4; NE, neutrophil elastase; TNF-α, tumor necrosis factor-α; LDGs, low-density granulocytes; DNase, deoxyribonuclease; PTMs, post-translational modifications; mtDNA, mitochondrial DNA; IFN I, type I interferon; FLS, fibroblast-like synoviocytes; HMGB1, high mobility group box 1; NETs, neutrophil extracellular traps; RA, rheumatoid arthritis; [RA], evidence validated in RA patients; [Ext], mechanism extrapolated from other autoimmune diseases. NETs-Mediated Atherosclerosis in RA RA is a chronic autoimmune disease characterized by systemic inflammation, and patients with RA face a significantly elevated risk of CVD, with atherosclerosis being the primary pathological basis.52,53 Accumulating preclinical and associative clinical evidence supports the hypothesis that NETs serve as a plausible pathogenic link between RA and accelerated atherosclerosis, mediating multiple pro-atherogenic processes through interactions with vascular cells, inflammatory mediators and autoantigens.52,54,55 However, this causal proposition remains incompletely validated in human RA cohorts. Endothelial Dysfunction and Vascular Injury NETs directly impair endothelial integrity, a critical early event in atherosclerosis.53,54 NETs-derived components, including histones, NE and MPO, disrupt the junctions between endothelial cells, endothelial-to-mesenchymal transformation induced by NETs has been reported in general atherosclerosis models but has not been directly verified in the context of RA.52,54 These alterations lead to vascular leakage and reduced endothelium-dependent vasorelaxation. Moreover, NETs activate endothelial cells via TLR and danger-associated molecular pattern (DAMP) signaling, upregulating the expression of vascular cell adhesion molecule-1 (VCAM-1) and pro-inflammatory cytokines such as IL-6 and TNF-α, which recruit monocytes and neutrophils to the vascular wall, amplifying local inflammation.53,56 In animal models, inhibition of PAD-4, a key enzyme for NETs formation, improves endothelial function and reduces atherosclerotic lesions, supporting a causal role of NETs in vascular injury in preclinical settings.52,54 Promotion of Inflammation and Plaque Progression Mechanistically, the following pro-atherogenic effects of NETs are well characterized in general atherosclerosis research, and their direct contribution to RA-associated atherosclerosis remains to be specifically validated. NETs contribute to the progression of atherosclerotic plaques by modulating macrophage function.52,55 The components of NETs such as double-stranded DNA and citrullinated proteins activate macrophages through TLR9 and NLRP3 inflammasome pathways, promoting their polarization to pro-inflammatory M1 phenotypes.55,56 These activated macrophages secrete IL-1β, IL-6, and TNF-α, which further enhance NETosis and lipid uptake, leading to the formation of foam cells and the enlargement of the lipid core within plaques.52,56 Additionally, NETs are localized in the rupture-prone regions of atherosclerotic plaques, where they degrade the fibrous cap via NE and matrix metalloproteinase-9 (MMP-9), increasing plaque vulnerability.52,54 Limited observational data suggest an association between NETs burden in coronary plaques and infarct size,53 but this correlation has not been definitively confirmed in dedicated RA patient cohorts, and further prospective studies are warranted. Thrombosis and Atherothrombotic Complications NETs exert pro-thrombotic effects that accelerate atherothrombosis, a major CVD complication in RA.53,54 NETs provide a scaffold for platelet aggregation and fibrin deposition, as their chromatin fibers bind von Willebrand factor (vWF) and fibrinogen.54,55 Moreover, NETs-associated tissue factor (TF) initiates the coagulation cascade, while NE cleaves tissue factor pathway inhibitor, further enhancing coagulation.53,55 Platelets, in turn, induce NETs formation via high mobility group box 1 (HMGB1) signaling, creating a reciprocal pro-thrombotic loop.54 In patients with RA, NETs are abundant in arterial thrombi, and reduced DNase activity (which degrades NETs) is associated with increased thrombotic risk.53,55 The pathogenesis of NETs-mediated atherosclerosis in RA is shown in Figure 2. To clarify the strength of supporting data and prevent overinterpretation of associational findings, Table 1 systematically summarizes the mechanistic evidence hierarchy for each proposed pathway, explicitly distinguishing RA-specific data from extrapolated evidence and indicating the overall level of confidence. The pathogenesis of NETs-mediated atherosclerosis in RA. Abbreviations: NETs; neutrophil extracellular traps; RA; rheumatoid arthritis; ROS, reactive oxygen species, [RA], evidence validated in RA patients; [Exp], evidence from experimental models; [Ext], mechanism extrapolated from other autoimmune diseases. Table 1Mechanistic Evidence Hierarchy for NETs in RA-Associated AtherosclerosisProposed PathwayStudy TypeRA-Specific EvidenceData SourceConfidenceEnhanced NETs formation in RAAutoantibody-mediated NETosis (ACPAs, immune complexes)In vitro + ex vivo patient assaysYes; validated in RA serum and synovial fluidPrimarily human ex vivoModerate–HighCytokine-driven NETosis (IL-33, TNF-α, IL-8/17)Functional assays + patient correlation studiesYes; cytokine levels correlate with NETs markers in RAHuman correlative + in vitroModerateFLS-neutrophil proinflammatory loopIn vitro co-culture + RA synovial tissue analysisYes; confirmed in RA-derived FLS and neutrophilsHuman ex vivo/in vitroModeratePAD4-mediated citrullination/carbamylationEnzyme activity assays + patient sample detectionYes; elevated PAD4 activity in RA patientsHuman + preclinical validationModerateImpaired NETs clearance (DNase 1/1L3)Enzyme activity + genetic association studiesYes; reduced DNase activity and susceptibility variants in RAHuman clinical/geneticModerateLDG-enhanced NETosisImmune phenotyping + ex vivo functional assaysYes; LDG subset enriched in RA with higher NETs capacityHuman ex vivoModerateNETs-driven atherosclerosis in RAEndothelial dysfunction and vascular injuryEndothelial cell assays + murine modelsPartial; endothelial dysfunction confirmed in RA, causal link shown in animalsMixed human/animalModeratePlaque progression and instabilityMurine atherosclerosis + human plaque analysisLimited; NETs burden correlates with infarct size in RAMixed human/animalModerateAtherothrombosisCoagulation assays + thrombosis models + human thrombiPartial; NETs abundant in RA arterial thrombiMixed human/animalModerateOxidized mtDNA immunostimulationSLE patient and murine studiesNo; only plasma mtDNA elevation confirmed in RAExtrapolated from other diseasesLow Mechanistic Evidence Hierarchy for NETs in RA-Associated Atherosclerosis Management of NETs-Mediated Atherosclerosis in RA The management of NETs-mediated atherosclerosis in RA requires a synergistic approach targeting both RA-related systemic inflammation, NETs formation and traditional CV risk factors. Given the central role of NETs as a link between RA pathophysiology and accelerated atherogenesis, therapeutic strategies should prioritize interfering with NETs biology while controlling disease activity to mitigate CVD morbidity and mortality in patients with RA.52,54 The following section stratifies interventions into established clinical measures and investigational NET-targeted approaches to clarify their current clinical positioning. Established Clinical Management Strategies These interventions are supported by robust clinical evidence, approved for routine use in RA or standard cardiovascular care, and represent the current standard of management for RA-associated atherosclerosis. Early Assessment of Atherosclerosis in RA Early and comprehensive evaluation of subclinical atherosclerosis is essential for preventing cardiovascular events in patients with RA.57 Routine cardiovascular risk stratification is recommended for all patients with RA at baseline, using guideline-endorsed adjusted conventional risk scores or RA-specific risk algorithms, consistent with the European Alliance of Associations for Rheumatology (EULAR) recommendations.58 Non-invasive imaging tests—including carotid ultrasound for carotid intima-media thickness (cIMT) and plaque detection, echocardiographic aortic elasticity assessment, and coronary artery calcium scoring—are not indicated universally for all RA patients. Instead, these imaging modalities should be considered as optional adjunctive tools, selectively applied to patients at intermediate or high cardiovascular risk, or those with suspected subclinical vascular damage, to refine risk classification and guide intensified preventive strategies.57,59,60 Conventional CVD Risk Control and Adjuvant Therapy Statins Statins exert pleiotropic anti-inflammatory effects beyond lipid lowering, including reducing NETs formation and modifying lipoprotein function in RA.61,62 Atorvastatin and simvastatin improve vascular function, reduce cIMT, and decrease oxLDL-induced NETosis in patients with RA.52,63 Notably, statins reduce proinflammatory high-density lipoprotein (piHDL) and enhance cholesterol efflux, counteracting the “lipid paradox” in the active stage of RA.53,64 Colchicine Low-dose colchicine (0.5 mg/day) has emerged as a potential therapy for atherosclerotic CVD, exhibiting anti-inflammatory effects, including the inhibition of NETs.65,66 In murine models, colchicine has been shown to reduce the burden of NETs within plaques, the size of necrotic cores and collagen content, thereby stabilizing unstable plaques.65 In patients with RA, colchicine attenuates NETs-induced endothelial inflammation and thrombosis,67 complementing biologic disease-modifying antirheumatic drugs (bDMARDs) by targeting NETs-mediated vascular injury.52 Large-scale long-term cohort studies in patients with RA may help confirm the cardiovascular benefits of low-dose colchicine, and its synergistic effects with bDMARDs could be further evaluated. Disease-Modifying Antirheumatic Therapies Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) TNF-α and IL-6 are key cytokines driving NETs formation in RA.68,69 Anti-TNF-α agents, such as infliximab and adalimumab, suppress the NETosis of neutrophils in RA, reduce circulating NETs biomarkers and improve endothelial function.70,71 Similarly, the IL-6 receptor inhibitor, tocilizumab, modulates NETs formation and attenuates the proatherothrombotic profile in patients with RA by reducing endothelial dysfunction and inflammation.38,71 These agents not only control the disease activity of RA but also mitigate NETs-mediated atherogenesis by targeting upstream inflammatory pathways.52,53 Janus Kinase (JAK) Inhibitors JAK inhibitors, such as tofacitinib and baricitinib, reduce the disease activity of RA by blocking cytokine signaling and have shown beneficial effects on lipid metabolism and atherosclerosis.72,73 In preclinical models, JAK inhibition decreases NETs formation and plaque burden,74 while clinical data demonstrates an improvement in the cIMT among patients with RA.73 Their ability to target both inflammation and NETs makes them a promising option for RA patients at high risk of CVD.53 The cardiovascular safety profile of JAK inhibitors is nuanced and not determined by dose alone. Multiple patient- and drug-related factors modify thrombotic, cardiovascular and malignancy risk, including older age (≥50 years), current smoking, pre-existing cardiovascular disease, baseline malignancy risk, and the specific JAK inhibitor agent used.75 Current clinical guidance recommends comprehensive baseline cardiovascular and malignancy risk stratification before initiating JAK inhibitors, with preferential use of biologic DMARDs in patients at elevated cardiovascular or malignant risk. While lower-dose regimens may carry a more favorable safety profile in selected populations, individualized risk assessment based on patient characteristics remains the primary consideration in treatment selection.76 Investigational NET-Targeted Therapeutic Approaches These strategies directly target NETs formation or clearance, but remain at the preclinical or early clinical research stage. They are not currently approved for routine clinical use in patients with RA-associated atherosclerosis, and further RA-specific clinical validation is required before clinical translation. PAD-4 Inhibitors PAD-4-mediated histone citrullination is a key step in NETs formation, making PAD inhibitors a direct therapeutic candidate. Preclinical studies have shown that Cl-amidine, a pan-PAD inhibitor, reduces NETs formation, inflammation and ACPAs response in collagen-induced arthritis models, while also attenuating atherosclerotic lesions in ApoE-deficient mice.54,70 In patients with RA, PAD-4 inhibitors decrease synovial NETs burden and ameliorates endothelial dysfunction, a critical early event in atherosclerosis.52,77 Although clinical data in patients with RA are limited, emerging evidence supports the potential of PAD-4 inhibitors to simultaneously target RA activity and NETs-mediated atherothrombosis.77,78 Notably, PAD4 inhibition only blocks PAD4-dependent NETosis and does not affect PAD4-independent NETs release pathways. Future clinical trials may help validate the clinical efficacy and safety of PAD-4 inhibitors. DNase Therapy DNase I degrades the DNA backbone of NETs, disrupting their proinflammatory and procoagulant functions.79 Preclinical evidence for the vascular protective effects of DNase therapy is primarily extrapolated from murine models of systemic lupus erythematosus, general atherosclerosis and myocardial ischemia–reperfusion injury, in which DNase I administration reduces NETs accumulation, plaque instability and infarct size.80,81 In RA, impaired NETs degradation contributes to persistent inflammation and vascular injury,54 and DNase I has been shown to dismantle NETs in synovial fluid and reduce endothelial activation.52 However, direct clinical evidence of DNase efficacy in RA-associated atherosclerosis is currently unavailable; a prior clinical trial in lupus nephritis failed to show significant benefits, further underscoring the need for RA-specific evaluation of tailored DNase delivery or combination strategies,82 highlighting the need for tailored delivery or combination with anti-inflammatory agents in RA-related atherosclerosis.53 Targeted delivery systems for DNase I might be explored, and combination with anti-inflammatory agents could potentially restore NETs clearance efficiency in patients with RA. Emerging Biomarker-Guided Risk Stratification NETs-derived biomarkers, such as Cit H3, cell-free nucleosomes and MPO-DNA complexes, are correlated with RA activity, ACPAs positivity and subclinical atherosclerosis.52,83 Circulating cell-free nucleosomes demonstrate high specificity in identifying early-stage atherosclerosis in RA.83 In addition, the degradation rate of NETs could predict the risk of CVD.84 Integrating these biomarkers with traditional CVD risk scores, like the Framingham and QRisk II scores, could improve risk stratification in RA, enabling targeted intervention.58,63 Despite these promising associations, several critical limitations must be acknowledged before NETs biomarkers could be recommended for routine cardiovascular risk stratification. First, there is a widespread lack of standardized detection protocols, harmonized assay platforms and universally accepted clinical cut-off values across studies, limiting comparability and clinical translatability. Second, these biomarkers lack disease specificity: circulating NETs markers could be elevated by multiple confounding conditions, including acute or chronic infection, active smoking, concurrent thrombosis, renal impairment, certain medications and variability in specimen handling and storage. Third, available data are predominantly derived from cross-sectional cohorts; large-scale longitudinal studies are still lacking to validate whether NETs biomarkers provide incremental predictive value beyond established conventional CVD risk factors and conventional inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate. Finally, it remains unproven whether biomarker-guided risk reclassification translates into improved clinical outcomes. Table 2 provides a structured overview of all management strategies, stratified by clinical maturity, to clearly distinguish established standard care from investigational NET-targeted approaches and prevent misinterpretation of experimental therapies as clinically available options. Table 2Summary of Management Strategies for NETs-Mediated Atherosclerosis in RAInterventionNET-Related MechanismEvidence BaseCV FindingsLimitationsClinical StatusEstablished clinical therapiesAnti-TNF-α agentsSuppress upstream inflammation and neutrophil activationRA patient cohortsReduced circulating NET markers; improved endothelial functionIndirect NETs effectStandard of careIL-6 receptor inhibitor (tocilizumab)Attenuate cytokine-driven NET formationRA patient cohortsImproved endothelial function; reduced pro-thrombotic profileIndirect NETs effectStandard of careJAK inhibitorsBlock cytokine signaling; reduce NET formationPreclinical models + RA patient cohortsImproved cIMT in RA; reduced plaque burden in miceNuanced CV/malignancy risk (modified by age, smoking, baseline risk)Standard of care (with risk stratification)StatinsReduce oxLDL-induced NETosis; pleiotropic anti-inflammationRA clinical studies + meta-analysesImproved vascular function; reduced cIMTNETs effect is secondaryStandard CV careLow-dose colchicineInhibit NET formation; stabilize plaquesMurine models + small clinical studiesAttenuated NET-mediated endothelial injury and thrombosisLimited large-scale RA CV outcome dataAdjunctive off-label useInvestigational NET-targeted therapiesPAD4 inhibitorsBlock histone citrullination; directly inhibit NETosisCIA + ApoE−/− mouse models; early-phase dataReduced synovial NETs; attenuated atherosclerosis in miceLimited RA clinical data; no CV outcome trialsPreclinical/early investigationalDNase I therapyDegrade NET DNA scaffold; disrupt pro-coagulant functionMurine models; ex vivo RA synovial fluidReduced plaque instability/infarct size in animalsNo RA-specific CV efficacy; negative lupus nephritis trialPreclinical/investigationalNET biomarkers (Cit H3, MPO-DNA)Correlate with RA activity and subclinical atherosclerosisObservational RA cohortsAid early detection of subclinical atherosclerosisNo standardized protocols/cut-offsEmerging/investigational Summary of Management Strategies for NETs-Mediated Atherosclerosis in RA Discussion RA is increasingly recognized as a systemic inflammatory disorder closely linked to accelerated atherosclerosis, with NETs emerging as a plausible pathogenic bridge between these two conditions. As summarized in this review, NETs formation in RA is orchestrated by multiple interconnected factors, including autoantibodies, proinflammatory cytokines, cellular crosstalk, post-translational modifications, impaired clearance and neutrophil heterogeneity—which collectively contribute to sustained NETs accumulation.26,30,39,85 Accumulating mechanistic, preclinical and associative evidence indicates these NETs may contribute to atherosclerosis progression through three proposed pathways: endothelial dysfunction via cytotoxic components, promotion of inflammatory plaque progression and instability and induction of pro-thrombotic cascades.52,54,55 However, current human evidence supporting NETs as a direct pathogenic bridge remains largely associational, lacking formal mediation analysis and RA-specific interventional data to confirm causality. Additionally, several mechanistic insights into NET-mediated vascular damage are extrapolated from other inflammatory diseases such as systemic lupus erythematosus, and direct validation in RA-specific cohorts remains an important research gap. Several caveats temper the supportive evidence. First, the association of circulating NETs markers with subclinical atherosclerosis loses independence in some RA cohorts after adjustment for systemic inflammation.86 Second, a DNase I trial in lupus nephritis failed to show efficacy, casting doubt on the translational benefit of NET-degrading therapies in autoimmune disease. Third, PAD4 inhibitors have inconsistent RA efficacy in early trials, with no human cardiovascular outcome data. Finally, non-specific NET suppression may carry unassessed risks given NETs’ physiological role in host defense. The management of NETs-mediated atherosclerosis in RA demands a multimodal approach that synergizes targeting NETs biology, suppressing RA-related systemic inflammation, and controlling traditional CVD risk factors. Preclinical and emerging clinical evidence supports the potential of PAD-4 inhibitors and DNase therapy to directly interfere with NETs formation and clearance, while anti-TNF-α agents and JAK inhibitors indirectly mitigate NETs-driven atherogenesis by dampening upstream inflammatory signaling.54,70,73 Notably, most interventions reducing NETs also attenuate inflammatory pathways, and isolated NETs targeting has not been shown to mitigate chronic atherosclerosis independently.77,87 Complementary strategies such as statins and low-dose colchicine further enhance vascular protection through pleiotropic anti-inflammatory and NETs-inhibitory effects.63,65 Notably, NETs-derived biomarkers offer promise for improved risk stratification, enabling personalized intervention in patients with RA at high risk of CVD.58,83 But their clinical implementation is currently constrained by limited assay standardization, susceptibility to multiple confounding factors and a lack of validated incremental predictive value over conventional risk tools. Further prospective studies are needed to establish whether biomarker-guided stratification enables personalized intervention and improves outcomes in patients with RA at high risk of CVD. Despite these advances, several limitations persist. Clinical data on NETs-targeted therapies, such as PAD-4 inhibitors, are still limited in patients with RA, and the optimal combination of anti-RA agents, NETs modulators and traditional CVD medications remains to be defined. Additionally, the precise mechanisms underlying NETs clearance impairment and neutrophil heterogeneity in RA-associated atherosclerosis require further elucidation. Future research should prioritize large-scale clinical trials to validate the efficacy of NETs-targeted strategies, as well as explore the role of novel biomarkers in monitoring treatment responses and CVD outcomes. In conclusion, current evidence supports NETs as a biologically plausible candidate mechanism linking RA-related systemic inflammation to vascular injury and accelerated atherosclerosis, as well as a promising exploratory biomarker candidate. Importantly, NETs-targeted treatment remains experimental and has not been demonstrated to reduce cardiovascular events or mortality in patients with RA. A comprehensive strategy integrating optimal RA inflammation control, standard cardiovascular risk management, and investigational NETs-modulating approaches holds great potential to reduce CVD morbidity and mortality in patients with RA. Further translational and clinical studies are warranted to refine these approaches and improve long-term outcomes for this high-risk population. Funding Statement This research was funded by the Zhejiang Provincial Key Clinical Specialty Construction Project-Department of Cardiology (Grant No. 2024-ZJZK-001) and the Joint Fund of Zhejiang Provincial Natural Science Foundation of China under (Grant No. 2025CGZ040). Data Sharing Statement Data availability is not applicable as no new data were generated or analyzed for this study. Author Contributions Yezhou Qian: Conceptualization; Investigation (literature search and evidence screening); Writing – original draft. Feige Nian: Data curation (evidence stratification and table organization); Writing – review and editing. Hao Zhang: Formal analysis (evidence hierarchy evaluation); Visualization; Supervision; Writing – review and editing. BinFeng Mo: Conceptualization; Project administration; Supervision; Visualization; Funding acquisition; Writing – review and editing. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. References Associated Data Data Availability Statement Data availability is not applicable as no new data were generated or analyzed for this study.